官方服务：
资源简介：
Determined was the diversity of mutation-specific TCRs of tumor bearing mice (TBM). Isolated were tetramer-binding CD4 T cells followed by single cell TCR-sequencing using 10x.
应用场景：
创建时间：
2024-05-20
相关数据集
DataSheet1_Comprehensive Profiling Analysis of CD209 in Malignancies Reveals the Therapeutic Implication for Tumor Patients Infected With SARS-CoV-2.xlsx
Coronavirus disease 2019 (COVID-19), which is known to be caused by the virus severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is characterized by pneumonia, cytokine storms, and lymphope
NIAID Data Ecosystem40
BHLHE40 Regulates T Cell Effector Function Required for Tumor Microenvironment Remodeling and Immune Checkpoint Therapy Efficacy. BHLHE40 Regulates T Cell Effector Function Required for Tumor Microenvironment Remodeling and Immune Checkpoint Therapy Efficacy
Using both global and conditional knockout mice, we demonstrated that the transcription factor Basic Helix-Loop-Helix Family Member E40 (BHLHE40/DEC1) is required in T cells for rejection of mouse syn
NIAID Data Ecosystem20
Neoadjuvant chemotherapy alters the compositions and molecular features of peripheral and tumor-infiltrating immune cells in breast cancer revealed by single cell RNA sequencing. Single cell atlas of breast cancer treated with neoadjuvant chemotherapy
It is unclear how neoadjuvant chemotherapy (NACT) impacts the evolution of circulating or tumor-infiltrating immune cells over time in breast cancer. To address this question, we performed single cell
NIAID Data Ecosystem10
Table_4_A Novel Prognostic Signature Associated With the Tumor Microenvironment in Kidney Renal Clear Cell Carcinoma.xls
BackgroundThe tumor microenvironment (TME) is a complex and evolving environment, and the tumor immune microenvironment in kidney renal clear cell carcinoma (KIRC) has a strong suppressive profile. Th
NIAID Data Ecosystem30
Table7_Identification and Comprehensive Prognostic Analysis of a Novel Chemokine-Related lncRNA Signature and Immune Landscape in Gastric Cancer.XLS
Gastric cancer (GC) is a malignant tumor with poor survival outcomes. Immunotherapy can improve the prognosis of many cancers, including GC. However, in clinical practice, not all cancer patients are
NIAID Data Ecosystem10
